I-SPY 2--A Glimpse of the Future of Phase 2 Drug Development?

The I-SPY 2 breast cancer trials assess activity of new agents by adaptive randomization, applying criteria for success on a surrogate end point to predict success in confirmatory trials. Innovative designs may speed progress and eliminate waste in drug development.

[1]  George E. P. Box,et al.  Empirical Model‐Building and Response Surfaces , 1988 .

[2]  D. Louis,et al.  Influence of unrecognized molecular heterogeneity on randomized clinical trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Gray,et al.  Multi-Arm Clinical Trials of New Agents: Some Design Considerations , 2008, Clinical Cancer Research.